Versant Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Versant Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.32K	Sell	399 -1,604	-80%	-$15.1K	﹤0.01%	2528
2026 Q2	$20K	Buy	2,003 +1,521	+316%	+$13.8K	﹤0.01%	1928
2026 Q1	$4.59K	Buy	482 +328	+213%	+$2.55K	﹤0.01%	2406
2025 Q4	$1.2K	Hold	154	–	–	﹤0.01%	2513
2025 Q3	$1.17K	Hold	154	–	–	﹤0.01%	2483
2025 Q2	$1.38K	Buy	+154	New	+$1.43K	﹤0.01%	2448
2023 Q3	–	Sell	-59	Closed	-$415	–	1948
2023 Q2	$415	Buy	+59	New	+$473	﹤0.01%	1873

Other funds holding BCRX

WCM

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

MBI

May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return

CIM

Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Versant Capital Management's BCRX Position: Q3 2026 in Review

Versant Capital Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 80% in Q3 2026, selling an estimated $15.1K and leaving 399 shares worth $3.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2528.

Versant Capital Management first reported a position in BCRX in Q2 2023 and has held it in 7 quarters since. The position peaked at $20K in Q2 2026. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

Versant Capital Management held 399 shares of BioCryst Pharmaceuticals worth $3.32K as of Q3 2026.
Versant Capital Management sold 1,604 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $15.1K.
BioCryst Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2528 holding.
Versant Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Versant Capital Management's BioCryst Pharmaceuticals position peaked at $20K in Q2 2026.
11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.